Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
ClinicalTrials.gov Identifier |
NCT03942328 |
Institution Name |
Mayo Clinic |
Full Institution Address |
200 First Street SW Rochester Minnesota 55905 United States |
Institution Phone |
(507) 284-2511 |
Institution Website |
https://www.mayoclinic.org |
Principal Investigator |
Lewis R Roberts, M.B., Ch.B., Ph.D |
Principal Investigator Phone |
(507) 266-3239 |
Principal Investigator Email |
Roberts.Lewis@mayo.edu |
Additional Principal Investigators |
|
Study Coordinator |
Jaclynn Maria Wessling |
Study Coordinator Phone |
(507) 538-4545 |
Study Coordinator Email |
Wessling.Jaclynn@mayo.edu |
Study Overview |
Early phase 1 study evaluating the safety of autologous dendritic cells (immune cells generated from patients' own white blood cells, grown in a special lab, and trained to stimulate the immune system against the tumor) and a vaccine (Prevnar) in treating patients with liver cancer that cannot be removed by surgery after undergoing radiotherapy. |
Enrollment Information |
26 |
Study Start Date |
20190517 |
Study End Date |
20261231 |
Study Purpose |
|
Inclusion Criteria |
|
Exclusion Criteria |
|
Required Tests Prior to Study |
|
Potential Side Effects |
|
Financial Assistance Available |
No |